MetFi

The history of MetFi (METFI) is not extensively documented, particularly regarding its founding team, which remains anonymous. However, here are some key events and milestones:

• 2022, Q2: MetFi launched its smart contract, marking the beginning of its decentralized autonomous organization (DAO) focused on investing in and incubating Metaverse and Web3 projects.
• 2022, End: Web3 projects could apply for funding from the MetFi community, leading to the first funded project, Big Time, followed by investments in AngelBlock, iMe-X, Evermoon, The Sandbox, and Sona Protocol.
• 2023: MetFi locked its liquidity for two years to prevent rug pulls and ensure community trust. This period also saw the introduction of lending, borrowing, and MultiSig treasury tracking features. The METFI token was listed on Gate.io.
• 2023: MetFi launched MetaQuiz, an educational game for community members to test their skills and win prizes.

These events highlight MetFi's rapid growth and its commitment to fostering a community-driven ecosystem for Web3 and Metaverse projects.

Metformin, commonly known as MetFi (METFI), is a medication used to manage type 2 diabetes. It works by helping the body to respond better to insulin, which is a hormone that regulates blood sugar levels. Here is a detailed explanation of how metformin works:

Metformin primarily reduces the amount of glucose produced by the liver. The liver produces glucose through a process called gluconeogenesis, where it converts non-glucose molecules like amino acids and lactate into glucose. Metformin inhibits this process, thereby reducing the amount of glucose released into the bloodstream.

Metformin also opposes the action of glucagon, a hormone that stimulates the liver to release stored glucose into the bloodstream. By inhibiting glucagon, metformin further reduces glucose production and release from the liver.

Metformin increases the body's sensitivity to insulin. This means that the body's cells become more responsive to insulin, allowing glucose to enter the cells more efficiently. As a result, the body can better use the glucose it produces, reducing blood sugar levels.

Metformin activates an enzyme called adenosine monophosphate kinase (AMPK). AMPK plays a crucial role in regulating cellular energy metabolism. When activated, AMPK inhibits key enzymes involved in glucose production and storage in the liver, while stimulating glucose uptake in muscles. This helps to reduce glucose levels in the bloodstream.

Metformin also increases peripheral glucose disposal, which means it enhances the body's ability to use glucose in the muscles and other tissues. This is achieved through increased non-oxidative glucose disposal, primarily in skeletal muscle.

The combined effects of metformin lead to a reduction in blood glucose levels. This is achieved without increasing insulin secretion, making it an effective treatment for type 2 diabetes. Additionally, metformin is associated with fewer side effects, such as weight gain, compared to other diabetes medications.

In summary, metformin works by reducing glucose production in the liver, increasing insulin sensitivity, activating AMPK, and enhancing peripheral glucose disposal. These mechanisms help to lower blood glucose levels and manage type 2 diabetes effectively.

MetFi (METFI) has several strengths that contribute to its potential as a promising investment opportunity:

1. Decentralized Governance: MetFi operates as a decentralized autonomous organization (DAO), which means that it is owned and controlled by its community. This decentralized governance model allows community members to participate in decision-making processes through voting, ensuring that the ecosystem is driven by collective input.

2. Utility NFTs: MetFi's NFTs provide a range of benefits, including tokens, staking rewards, airdrops, treasury assets, and early access to new projects. These utility NFTs incentivize users to participate in the ecosystem, contributing to its growth and sustainability.

3. Staking and Rewards: MetFi offers staking opportunities with rewards, such as METFI Multiplier Rewards, which are distributed to NFT owners every 12 hours. This encourages community engagement and provides additional income streams for investors.

4. Incubation of Web3 Projects: MetFi focuses on investing in and incubating promising Web3 and Metaverse projects, providing early-stage access to these startups. This positions MetFi as a key player in the development of the Web3 ecosystem.

5. Community Engagement: MetFi's community-driven approach fosters engagement through various mechanisms, including governance voting, staking, and rewards. This active community helps incubate and support projects, ensuring the long-term sustainability of the ecosystem.

6. Automation and Security: MetFi's platform is built on blockchain technology, utilizing 27 interconnected smart contracts to automate processes and reduce the risk of human error. This ensures a secure and efficient environment for transactions and decision-making.

These strengths collectively contribute to MetFi's potential for growth and its appeal as a promising investment opportunity in the Web3 and Metaverse sectors.

Metformin, commonly known as MetFi (METFI), has several risks and side effects associated with its use. Some of these risks include:

• Hypoglycemia (Low Blood Sugar): Metformin can cause hypoglycemia, especially when taken with other medications. Symptoms include nausea, vomiting, rapid heartbeat, and dizziness.
• Lactic Acidosis: Metformin can cause lactic acidosis, a severe and potentially life-threatening condition. Symptoms include abdominal discomfort, diarrhea, fast or shallow breathing, and muscle pain.
• Gastrointestinal Issues: Common side effects include nausea, stomach upset, and diarrhea.
• Kidney Problems: Elderly patients with kidney problems should exercise caution when taking metformin, as it may exacerbate kidney issues.
• Interactions with Other Medications: Metformin can interact with certain medications, such as statins, and may require dose adjustments or special precautions.
• Pregnancy and Breastfeeding: There is limited information on the safety of metformin during pregnancy and breastfeeding, and it is recommended to weigh the potential benefits against the potential risks.

It is essential to discuss these risks with a healthcare professional and carefully follow their instructions to minimize potential side effects.

• Dany Cadoux: Entrepreneuse and Slasheuse.
• Thierry MATHURIN: Co-Gérant Fédération Coaching Caraïbes.
• Frédérique Barral: Team member.
• Polar Bear: Founder, known for involvement in other scam projects like Tien Tien.
• Staffan Liback: Involved in MetFi, previously associated with OneCoin scammers.
• Stephan Steinkeller: Involved in MetFi, wanted by Italian authorities for OneCoin criminal fraud charges.
• Jairo Cornago Moreno: Former Winwheel promoter, involved in MetFi webinars.